IMMX — Immix Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00
- $54.94m
- $25.34m
- 31
- 21
- 27
- 16
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -0.973 | -1.15 | -24.4 | -8.23 | -15.6 |
Depreciation | |||||
Non-Cash Items | 0 | 0.575 | 23.2 | 0.624 | 2.57 |
Other Non-Cash Items | |||||
Changes in Working Capital | 0.182 | 0.166 | -0.391 | 0.195 | 1.65 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -0.79 | -0.405 | -1.59 | -7.41 | -11.4 |
Capital Expenditures | -0.007 | 0 | -0.001 | 0 | -0.052 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.007 | 0 | -0.001 | 0 | -0.052 |
Financing Cash Flow Items | — | 0 | — | 0.468 | -0.235 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1.05 | 0 | 18.8 | 3.23 | 15.5 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.272 | -0.343 | 17.3 | -4.21 | 4.07 |